



NH

# Tipiracil hydrochloride

Cat. No.:	A3875
CAS No.:	183204-72-0
Formula:	C9H12CI2N4O2
M.Wt:	279.12
Synonyms:	Tipiracil
Target:	Others
Pathway:	Thymidine phosphorylase
Storage:	Store at -20°C

## Solvent & Solubility

insoluble in DMSO, insoluble in EtOH,  $\geq$ 13.25 mg/mL in H2O

Preparing In Vitro Stock Solutions	Mass				
		Solvent	1mg	5mg	10mg
		Concentration			
	SLOCK SOLUTIONS	1 mM	3.5827 mL	17.9134 mL	35.8269 mL
		5 mM	0.7165 mL	3.5827 mL	7.1654 mL
		10 mM	0.3583 mL	1.7913 mL	3.5827 mL

HN

NH

HCI

0.

Please refer to the solubility information to select the appropriate solvent.

### **Biological Activity**

Shortsummary	Thymidine phosphorylase inhibitor		
IC <sub>50</sub> & Target			
In Vitro	Cell Viability Assay	310	
	Preparation method:	Constant Section Secti	
In Vivo	Animal experiment	Allow the second second	
	Animal models:	Xenograft-bearing nude mouse models of colorectal and gastric cancers	
	Dosage form:	150 mg/kg/day (combination of Trifluridine and Tipiracil Hydrochloride); p.o.;	
		b.i.d., for 14 days	
	Applications:	The tumor growth-inhibitory activity and RTV5 in mice administered TAS-102	

1 | www.apexbt.com

	(consisting of Trifluridine and Tipiracil Hydrochloride) with Oxaliplatin were
	significantly superior to those associated with either monotherapy in mice with
	colorectal (HCT 116 and SW-48 cells) and gastric (SC-2 and MKN74 cells)
	cancers. In vivo, TAS-102 alone was effective in MKN74/5FU cells, and its
	anti-tumor activity was substantially enhanced in combination with Oxaliplatin.
<b>210</b>	No significant decrease in body weight or toxicity was observed compared to
<b>SE</b> and the second	either monotherapy.
Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may
	slightly differ with the theoretical value. This is caused by an experimental
	system error and it is normal.

### **Product Citations**

See more customer validations on www.apexbt.com.

#### References

[1]. Tsukihara H, Nakagawa F, Sakamoto K et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep. 2015 May;33(5):2135-42.

#### Caution

#### FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.





APENBI

APExBIO Technology

www.apexbt.com 7505 Fannin street, Suite 410, Houston, TX 77054.

2 | www.apexbt.com



3 | www.apexbt.com